Latest Blogs

Jun 30, 2022
Establishing a reputation of humility, collegiality, and kindness ensures that people can seek you out earlier than later, which can prevent many complications and delays in care.
Jun 10, 2022
Dr. Khalid El Bairi reports on the educational presentations and exciting directions for future research from a recent event organized by young professionals in Taroudant, Morocco.
Jun 10, 2022
At the launch of an innovative partnership to combine medical oncology, hematology, and hospice and palliative medicine into a single fellowship program, Dr. Ramy Sedhom shares perspectives on the value of combined training and the critical function of this new training pathway.
May 26, 2022
"Several valuable lessons can be learned from the Syrian conflict and the immense experience of the Syrian American Medical Society’s (SAMS) efforts, coordination, and contributions developing oncology centers in northern Syria," said Dr. M. Bassel Atassi.
Subscribe to this column

Clifford A. Hudis, MD, FACP, FASCO

Clifford A. Hudis, MD, FACP, FASCO, is the CEO of ASCO, executive vice chair of Conquer Cancer, the ASCO Foundation, and chair of CancerLinQ. Prior to these roles, he served as chief of the Breast Medicine Service and an attending physician at Memorial Sloan Kettering Cancer Center and as a professor in the Department of Medicine at Weill Cornell Medical College. He is a past president of ASCO. His research interests include all areas of care related to breast cancer, with a focus on the development of novel systemic therapies and prevention interventions related to obesity and inflammation. Follow Dr. Hudis on Twitter @CliffordHudis.

Disclosure.

Jul 16, 2018
Broadening eligibility critera for cancer clinical trials will give more patients the opportunity to contribute to scientific research.
Jul 09, 2018
I am really pleased to have with us ASCO's Chief Medical Officer and Senior Vice President for a conversation focusing on right-to-try policies.
Jun 29, 2018
At the most recent Board of Directors meeting, we heard insightful presentations from participants in the Leadership Development Program, pivoted toward the execution of our 5-year strategic plan, and had a valuable conversation with NCI director Dr. Norman Sharpless.
May 24, 2018
While more biosimilars will likely be available in oncology in the next several years, their specific impact on patient care is going to depend on patient and provider acceptance of these agents.
May 17, 2018
ASCO would like to inform you of some changes to MOC that are a direct result of your input and our open, transparent collaboration with the ABIM. 
May 08, 2018
We examine how state-level health care policy may impact the care that we deliver to our patients with cancer, and why it's important for us to pay attention to and help shape bills and regulations moving in states.

Pages